If you are looking for...

“Ron Trahan took charge right from the start. He required no heavy lifting of us, yet played a truly critical role in helping to position our company effectively while putting—and keeping—us on the map.”
Jacques Séguin, MD, PhD, CoreValve Founder

Ronald Trahan Associates, Inc.

Welcome!

RONALD TRAHAN ASSOCIATES, INC., is an independent, full-service public and investor relations firm. Our business is focused on serving the Life Sciences industry, including the Biotechnology, Pharmaceutical and Medical Technology sectors.

BUSINESS PHILOSOPHY

There are two facts of life in the public relations business:

  1. Clients want results – now!
  2. They don’t want to pay a fortune for those results.

In short, companies hire public relations firms to make good things happen for them as cost effectively as possible.

RTA was founded on that principle: to provide experienced counsel in a timely fashion while garnering the right kind of attention for our clients, all at an affordable price. We strictly limit the number of clients we serve so that the agency’s president can personally interact with each RTA account as needed.

 

Partners

Medtech Insight, a division of Windhover Information, is the leading investor conference-organizer in the medtech space. Its ‘In3’ conferences in the U.S. and Europe have drawn more than 8,000 attendees and some 1,500 presenting companies since 2001— therein establishing Medtech Insight as the premier investment, partnering, and networking event in the medical technology industry. RTA has been a continuous Sponsor of Medtech Insight’s In3’ conferences since 2004.

OneMedPlace is the leading virtual community where life science companies in search of capital, visibility, and resources are able to connect with investors, strategic partners and service providers. OMP attracts more than 20,000 unique visitors per month; its Healthcare Investment Digest Research Report is mailed quarterly to 25,000 medtech industry execs and investors; its Med-Tech Sentinel Newsletter is emailed bi-weekly to 8,000 medtech execs and investors.

CLICK HERE TO LEARN WHY SUCCESS IS THE CONSEQUENCE OF PROCESS